WO2024261703 - BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF PATIENTS WITH XIAP DEFICIENCY OR CDC42 MUTATIONS
National phase entry:
Publication Number
WO/2024/261703
Publication Date
26.12.2024
International Application No.
PCT/IB2024/056062
International Filing Date
21.06.2024
Title **
[English]
BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF PATIENTS WITH XIAP DEFICIENCY OR CDC42 MUTATIONS
[French]
ANTICORPS BISPÉCIFIQUES DESTINÉS À ÊTRE UTILISÉS POUR TRAITER DES PATIENTS ATTEINTS D'UN DÉFICIT EN XIAP OU DE MUTATIONS DE CDC42
Applicants **
NOVARTIS AG
Inventors
BADMAN, Michael Keith
JUNGE, Guido
KIFFE, Michael
MCNAMARA, Elizabeth Akselrod
MEHES, Beata
SMITH, Rachel Claire
STEIN, Richard
WALDRON-LYNCH, Frank Derrick
Priority Data
63/509,905
23.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3651 | |
| EPO | Filing, Examination | 34204 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 13610 |
Total:
52,629
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of an CDC42 mutation or XIAP deficiency based autoinflammation or disease in a subject in need thereof.[French]
L'invention concerne des anticorps monoclonaux bispécifiques bivalents (bbmAb) ou des variants de ceux-ci destinés à être utilisés pour traiter ou pour soulager les symptômes d'une mutation de CDC42 ou d'une auto-inflammation ou d'une maladie liée à un déficit en XIAP chez un sujet en ayant besoin.